The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%. This report contains:

• Descriptions of diabetes therapeutics including drugs for diabetes and diabetes complications, diabetes diagnostics including blood glucose testing devices and supplies, and all other interventions
• The current global market status for diabetes therapeutics and diagnostics, with trends and forecasts for growth over the next 5 years
• Technological issues including the latest trends and a thorough patent analysis
• Discussion of predictions of a type II diabetes global epidemic
• Company profiles.

The global market for RNA interference (RNAi) was $145.2 million in 2007 and is expected to reach $174.5 million by the end of 2008. It should reach $3.6 billion by 2013, a compound annual growth rate (CAGR) of 83.4%. This report contains:

• Descriptions of various RNA interference (RNAi) technologies including research and development tools, diagnostics, therapeutics and agricultural applications.
• The current global market status of the RNAi industry, with trends and forecasts for growth over the next 5 years
• Analysis of the RNAi industry on a worldwide basis, both from a market and application perspective
• Discussion of state-of-the-art RNAi technologies and their future commercial potential
• Profiles of the main companies in the RNAi field.

The global market for vaccines is expected to reach $20 billion by the end of 2008. It should reach $34 billion by 2013, a compound annual growth rate (CAGR) of nearly 11%. This report contains:

• Descriptions of various human and veterinary vaccines that treat infectious diseases, chronic infections, cancer, auto-immune diseases, allergies, high blood pressure and addictions
• The current market status of the vaccine industry, with trends and forecasts for growth over the next 5 years
• The latest vaccine research findings in prophylactic and therapeutic areas
• Analysis of significant vaccine-related patents in the Unites States and Europe
• An overview of the regulatory environment.

The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%. This report contains:

• Descriptions of various types of monoclonal therapeutic and diagnostic antibodies in terms of their history in medicine, their types and technology categories
• The current market status for monoclonal therapeutic and diagnostic antibodies, trends and forecasts for growth over the next 5 years
• Technological issues including the latest trends and a thorough patent analysis
• Analysis of the monoclonal therapeutic and diagnostic antibodies industry on a worldwide basis, both from a market and application perspective
• Discussion of government support in major regions of the world.

The global market for cardiovascular diagnostics and therapy increased from $111 billion in 2006 to an estimated $119.8 billion in 2007. It should reach $192.4 billion through 2012, a compound annual growth rate (CAGR) of 9.9%. This report contains:

• Descriptions of various types of cardiovascular diagnostics such as in vitro tests and in vivo imaging techniques, devices such as drug eluting stents, and drugs such as Pfizer's blockbuster Lipitor
• The current market status of cardiovascular diagnostics, devices and drugs, along with trends and forecasts for growth over the next 5 years
• Technological issues including the latest developments and a thorough patent analysis
• Analysis of the cardiovascular diagnostics, devices and drugs industry, both from a market and application perspective
• Information about the major players in each market, including Medtronic and Boston Scientific in devices, Sanofi-Aventis and BMS in drugs, and Abbott in devices.

The global market for drug discovery technologies increased from $20.2 billion in 2006 to an estimated $22 billion in 2007. It should reach $32.5 billion by 2012, a compound annual growth rate (CAGR) of 8.2%. This report contains:

• Descriptions of various drug discovery-related products including bioanalytical instruments, high throughput screening, informatics and microarrays
• The current market status of drug discovery technologies, trends and forecasts for growth over the next 5 years
• Discussion of new methods of research important to the market including compound discovery, compound optimization, efficacy testing in vitro and in vivo, toxicology testing, pharmacokinetics, and stability testing
• An analysis of patents and their importance to the industry.

The global market for biomarkers increased from $4.8 billion in 2006 to an estimated $5.6 billion by the end of 2007. It should reach $12.8 billion by 2012, a compound annual growth rate (CAGR) of 18%. This report contains:

• Descriptions of various types of biomarkers including genomics, proteomics, bioformatics and metabolomics
• The current market status of biomarkers, trends, and forecasts for growth over the next 5 years
• Technological issues including the latest trends and findings in different therapeutic research areas
• An examination of the regulatory role of different federal agencies in U.S., Europe and the rest of the world that play an active role in biomarker discovery research
• Analysis of the biomarkers industry on a global basis, both from a market and application perspective.

The global market for blood disorder treatments increased from $34.8 billion in 2006 to an estimated $36.7 billion by the end of 2007. It should reach nearly $44.0 billion by 2012, a compound annual growth rate (cagr) of 3.9%. This report contains:

• Descriptions of various types of blood disorder treatments for anemia, hemophilia, neutropenia and thrombosis
• The current market status of blood disorder treatments, trends and forecasts for growth over the next 5 years
• Discussion of new technologies with a thorough patent analysis
• Analysis of the major overhaul of the U.S. Food and Drug Administration's approval process for blood disorder treatments
• Profiles of major players in the blood disorder treatment market.

The global orphan drugs market reached $58.7 billion in 2006, growing by 8% from $54.5 billion in 2005. It is expected to grow at a compounded annual growth rate (CAGR) of 7% to reach $81.8 billion by 2011. This report contains:

• An overview of orphan drug criteria, the history of Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends
• Detailed discussion of successful orphan products and a discussion of specific rare diseases for which orphan drugs exist
• Analysis of most promising therapeutic areas in the industry and leading orphan drugs in these therapeutic areas
• Global sales projections through 2011 for as many as 50 orphan drugs with sales exceeding $200 million
• Profiles of key players in the market and their market shares
• Technology trends analysis within orphan drugs market.

The global market for biochips increased from $1,637.5 million in 2006 to an estimated $2,115.6 million by the end of 2008. It should reach $3,840.7 million in 2013, a compound annual growth rate (CAGR) of 12.7%. This report contains:

• Descriptions of various biochips including current and potential applications
• The current market status of biochip products, trends and forecasts for growth over the next 5 to 10 years
• Technological issues, including the latest advances
• A discussion of driving forces in the biochip industry on a global basis, including large-scale integration, research initiatives and drug discovery
• An examination of biochip companies and industry alliances.

U.S. sales of anti-counterfeiting packaging technologies to the drug and food industries amounted to almost $34.2 billion in 2006. Sales are projected to reach $43 billion in 2012, representing a compound annual growth rate (CAGR) of 3.2% over the 2007 to 2012 period. This report contains:

• Descriptions of anti-counterfeiting packaging technologies and their potential applications
• The current U.S. market status of anti-counterfeiting technologies, trends, with forecasts for growth over the next 5 years
• Technological issues, including the latest developments
• A discussion of anti-counterfeiting initiatives including regulatory provisions, secure business practices, consumer education, and increased collaborative surveillance by domestic and international law enforcement agencies
• Profiles of major manufacturers/suppliers of authentication and track and trace packaging technologies.

Worldwide revenue for contract manufacture of prescription drugs (dosage forms) for 2004 was $11.1 billion, which is projected to increase at a compound annual growth rate (CAGR) of 9.4%, reaching $22.5 billion by the end of 2011. This report contains:

• The current market status for contract manufacturing, research, and packaging and forecasts for growth through 2011
• Discussion of the advantages and disadvantages of outsourcing
• Technological issues including the latest trends and developments
• Descriptions of each market's need for outsourcing, risks and regulatory environment.
• A break down of revenues by the bulk as well as by the dosage forms of solid, liquid and semisolid.

The global pain-management market is worth around $30.9 billion in 2007. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.63% to reach $40.6 billion by the end of the forecast period, 2012. This report contains:

• The major types of pain-management methods, including drugs (non-opioids, opioids, anticonvulsants, and antidepressants) and devices (transcutaneous electrical nerve stimulation (TENS), spinal cord stimulator (SCS), peripheral nerve stimulator (PNS), and intrathecal pumps)
• Analysis of each type of pain-relief technique, determining its current market status, its impact on future markets, and growth over the 5-year period 2007 through 2012
• Technological issues, including the latest trends, plus other influential factors, such as patents, new products, and other adjuvant techniques of pain management.

The chemical compounds used to make excipients are valued at $4.3 billion market value for 2011, up from $3.5 billion in 2006. The dominance of USP water, particularly water for injection, skews the market volume and sets the pace for the anticipated 5.1% average annual market volume growth rate over the next five years. This report contains:

• General information on inert ingredients, the types of technologies used to make them, their uses, and regulatory influences
• Excipients by chemical compounds, functional uses, delivery systems, and finished products
• Market environment, strategies, influences, and shares, international aspects, and other related factors
• Five year market forecasts through 2011 of compounds, delivery systems and finished products
• Company profiles that summarizes the leading industry participants.

The global market for neurological disease treatment and medication was worth $12.6 billion in 2006 and will reach $14 billion by 2007. At a compound annual growth rate (CAGR) of 11.6%, the global market will be worth almost $24.3 billion by 2012. This report contains:

• An analysis of the trends in drug discovery and development for the neurodegenerative disorders
• An overview of the global neurological disorders treatment market which provides definitions and a structure for the industry
• Provides details for the treatment markets of specific diseases such as Alzheimer's, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, muscular dystrophy, and other, rarer neurological disorders
• Offers a detailed analysis of patents as well as important technological developments
• A review of government regulations
• Profiles the most important companies in the industry today.

The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%. This report contains:

• An examination of the major markets for antifungal applications in human healthcare, veterinary healthcare, agriculture and the environment/buildings
• Analysis of each market segment on the global level, with current market status, and forecasts for growth over the next five years to 2012
• Highlights and reviews of FDA restrictions, government legislation, as well as discussions on fungal resistance and changes in consumer preferences, such as a greater demand for OTC medications and/or natural and alternative remedies
• Presentation of new drug and patent applications, new methods of drug administration, drug discovery and development, and various clinical trials and applications
• Profiles for important companies

The global market for immunotherapies to treat cancer was worth $19.6 billion in 2006 and will reach $23.7 billion by the end of 2007. At a compound annual growth rate (CAGR) of 9.5%, the global market will be worth more than $37.2 billion by 2012. This report contains:

• Analyses of products and applications in the cancer immunotherapy sector, including biological response modifiers (cytokines), monoclonal antibody-based products, therapeutic vaccines and other cancer immunotherapies.
• An overview of the global market, including historical data for cancer treatment and therapies, the latest market trends, and 5-year forecasts and estimates through 2012
• A section on industry structure with strategies employed by Big Pharma as well as top-selling drug patent expirations and how this relates to the overall pharmaceutical industry and biotechnology companies in particular
• Sections on products and applications with synopses of more than 100 cancer immunotherapy drug and vaccine products, including those currently marketed and those in Phase III or later development
• Analyses of patents within the past few decades
• Profiles for important businesses.

The U.S. in vitro toxicity (predictive toxicity) testing market has been valued at $765 million in 2006. At a compound annual growth rate (CAGR) of 14.4%, the total U.S. market will grow to reach $1.5 billion by 2011. This report contains:

• An overview of the in-vitro toxicology testing market, explaining basic principles and practices, definitions, classes of tests, and the different types of toxicology
• A technical overview that describes toxicology testing strategies, the various toxicology categories, and alternatives to the standard toxicology methods
• An in-depth review of the current market status, historical market data, compound annual growth rates, and forecasts to 2011
• Information on specific technology in the markets, including revenues and developments
• A thorough analysis of patents and profiles of the major players.

The total U.S. sales of media, sera, and reagents for biotechnology was $979 million in 2005 and almost $1.1 billion in 2006. At a compound annual growth rate (CAGR) of 8.9%, this market will grow to reach more than $1.6 billion in 2011. This report contains:

• An overview and analysis of the major types of media, sera and reagents used in biotechnology
• Global market forecasts for the industry, including current and historical data as well as 5-year market projections to 2011
• Review of the latest trends in technology, the latest important discoveries, and ideas and estimates for the future
• A detailed analysis of important patents within the past several decades
• Company profiles for the major industry players.

The global market for epigenomics was $161.8 million in 2005 and $263.2 million in 2006. The market will cross $385 million by 2007 and at a compound annual growth rate (CAGR) of 60.4% will reach nearly $4.1 billion by 2012. This report contains:

• The major epigenomics technologies and developments that are likely to become commercialized within the next five years
• Provides detailed market information for the global epigenomics market including historical data, current information, and projections to 2012
• Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs, and cloning/tissue engineering
• Discusses the market in terms of important medical applications such as biomarkers, cancer therapy, and reproductive technology
• Offers a detailed review of important patents and technologies
• Profiles the most competitive businesses in the industry.

The global market for prescription endocrine and metabolic disease drugs was $66.2 billion in 2005 and $72.3 billion in 2006. At a compounded annual growth rate (CAGR) of 5.2%, the market will reach $96.4 billion by 2011. This report contains:

• The major current and emerging markets for prescription drugs for endocrine and metabolic diseases, including hypertension, infertility, thyroid diseases, hypercholesterolemia, and obesity
• Historical market data from 2004, 2005, and 2006, in addition to five-year market forecasts with compounded annual growth rates through 2011
• Discusses applications as well as current and upcoming technology and trends
• Provides detailed patent analysis and profiles of the major companies in the biotechnology and pharmaceutical industries that provide products for the diseases covered in this report.

The total U.S. market for advanced wound care technologies was worth more than $2.3 billion in 2005. By the end of 2006 the market will reach almost $2.6 billion, and over a five-year period will grow at an average annual growth rate (AAGR) of 12.3% to reach $4.6 billion in 2011. This report:

• Provides an analysis of and quantitative market forecast for advanced wound care products, including wound types by demographic category.
• Covers all key market segments: acute wounds, chronic wounds, and burn wounds. The markets for biological dressings; surgical sealants and glues; synthetic dressings; other wound healing products; and wound healing devices are all analyzed and forecasts provides to 2012.
• Includes all significant wound care consumables and wound-healing devices.
• Includes detailed market analysis and competitive analysis, and information about significant products, players, issues and trends, and other information affecting the wound care industry.
• Includes industry structure, market shares, company profiles and patent analysis.

The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%. This report contains:

• Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials
• Market trends and five-year forecasts with projections through 2011
• Examination of current technologies underlying the market and details the effects of new technologies on this market
• Profiles of the major companies involved in the production and modification of protein drugs.
• An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.

The global market for herbal supplements was $5.5 billion in 2005 and $5.6 billion by the end of 2006. Growing at an average annual growth rate (AAGR) of 1.7%, this market sector will cross just over $6.1 billion by 2011. This report contains:

• The major current and emerging markets for herbal supplements, prescription drugs and (where applicable) OTC treatments
• An overview section that provides a discussion of the emergence of the herbal supplements market, U.S. and overseas regulations and guidelines relating to this market, sources of raw materials and concerns about sustainability of herbal harvesting practices
• A global forecast for the herbal supplement and OTC market, with a five-year forecast date to 2011
• The latest company profiles for the top companies in the market
• A detailed patent analysis.

The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011. This report contains:

• An overview of the major types of drug delivery systems used in the health industry
• Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
• Discussion of the technological issues, including the latest trends and developments
• Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
• Profiles of the major players within the industry and a detailed patent analysis.

The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011. This report contains:

• A thorough evaluation of the U.S. prescription ophthalmic pharmaceutical, device, diagnostic, and surgical market, with forecasts to 2011
• Market analysis focused on specific diseases and conditions such as cataract, glaucoma and refractive treatments
• Information regarding incidence and prevalence of eye conditions and risk factors associated with those conditions
• Examination of research and development activities with an emphasis on segments offering benefits to aging populations
• Profiles of the major companies in the industry as well as a detailed patent analysis.

Spending for clinical trials in the U.S. was nearly $24 billion in 2005. By 2006 this number will rise to $25.6 billion and then $32.1 billion in 2011, an average annual growth rate (AAGR) of 4.6%. This report contains:

• An overview of clinical development phases, the regulatory issues involved and the factors influencing clinical trial costs
• An in-depth analysis of the U.S. market for clinical trials that reviews historical data, market trends, and forecasts through 2011
• Highlights for new and upcoming technologies and developments that could have an impact on the clinical trials business
• Profiles of the major players in the business.

Global revenues for enzyme inhibitors were $32.1 billion in 2005. At an average annual growth rate (AAGR) of 5.1%, this market will cross $43 billion by 2011. This report contains:

• The major current and emerging therapeutic markets for enzyme inhibitors used in human therapeutics,
• A discussion of the biochemistry for enzyme inhibitors and classes of enzyme inhibiting products with broad current or potential therapeutic applications or large markets,
• A synopsis of more than 100 enzyme inhibitors, including those currently marketed and those in Phase II or later development,
• An overview of the leading indications for available and emerging enzyme inhibitors. These include selected indications for asthma and chronic obstructive pulmonary disease (COPD), cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related inflammatory diseases,
• Forecasts for the global market, through 2011,
• Company Profiles emphasizing companies that lead the pharmaceutical and biotechnology industry in the research and development of enzyme-inhibiting drugs.

The area most likely to see strong growth in the next five years is the one involving collaborations between large and small companies. Such collaborations were worth $13 billion in 2005, will increase to $14.4 billion in 2006 and reach $22 billion in 2010. This report:

• Analyzes the newly emerging industry in proteomics.
• Provides an overview of the market and a brief discussion of relevant scientific principles.
• Discusses current and future investment trends for the U.S. and the importance of each new method of research to the overall market.
• Analyzes patents and their importance to the industry.
• Considers investment by angel investors and venture capitalists, collaborations and mergers and acquisitions.
• Examines the relative merits of systems biology, a new approach and potential "next big thing" in the industry.
• Presents appendices that contain directories of companies and investors, as well as profiles of companies given significant coverage in the report.

The global market for plant-derived drugs was worth an estimated $18 billion in 2005. BCC expects this figure to grow to nearly $19 billion in 2006 and more than $26 billion by 2011, at an AAGR of 6.6% between 2006 and 2011. This report:

• Identifies and classifies the plant-derived drugs that have been commercialized to date.
• Analyzes the historical and current volume and value of shipments of each of these drugs in specified geographical markets.
• Identifies and evaluates the impact of factors that will drive future demand for plant-derived drugs.
• Describes plant-derived drugs that are currently in the clinical testing or approvals stage and assesses the probability that they will be commercialized successfully in the next 5 years.
• Contains forecasts for the global volume and value of plant-derived drug shipments and their markets through 2011
• Identifies the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years.

By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%. This report:

• Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics.
• Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2010.
• Identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis.
• Covers some of the most significant issues, trends and market factors.
• Profiles the top companies and major players in the market.

The market for anti-inflammatory drugs was $21.9 billion in 2005 and is projected to reach $35.5 billion in 2010 at an average annual growth rate (AAGR) of just over 10%. This report:

• Analyzes and assesses marketed and in-development prescribed systemic anti-inflammatory drugs.
• Provides an overview of the categories of anti-inflammatory drugs, including biological anti-inflammatory products, their methods of activity, usage and sales.
• Offers a forecast for the future of the market as well as forthcoming technology in various stages of development.
• Provides a detailed structure of the industry.
• Profiles market leaders of the industry.

The total number of new drugs approved by the FDA and EMEA dropped to 121 in 2005. Approvals will increase to 201 by 2010, at an AAGR of 10.7%. The report contains:

• A discussion of the regulatory environment on both and national and global levels.
• Analysis of each market by drug category for approvals and surveillance
• An outline and timeline of the process involved for approval of new pharmaceuticals by the FDA, BLA, and EMEA
• Analysis of worldwide commercial applications of biopesticides and their markets with forecasts to 2010
• Market shares of major companies as well as profiles and contact information for major players in the field.

The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. Rising at an average annual growth rate of 7.3%, the market is expected to reach $22.8 billion in 2009. The report contains:

• An overview of gastrointestinal disorders in the U.S.
• An overview of the gastrointestinal system and brief explanations of disorders, citing risk factors, where applicable; also cites incidence and mortality
• Discusses current pharmaceutical treatments, market size and market participants in both the prescription and over-the counter arenas
• Coverage of potential treatments now in R&D
• Analysis of market potential with forecasts to 2009
• A description of the industry in detail, its relationship to the healthcare industry, its participants and future trends.

The worldwide market for pharmacogenomics reached $1.24 billion in 2004 and is projected to rise at an average annual growth rate of 24.5% to reach $3.7 billion by 2009. The report contains:

• Detailed descriptions and analyses of the SNP identification process, genotyping technologies and pharmacogenomics-related diagnostic tools
• Determinations of the major players and current market status
• Analysis of how pharmacogenomics is translating into new medical therapies for specific disease targets
• Growth forecasts through 2009
• Emphasis on scientific challenges and advances, including the latest trends
• Examination of government regulations, major collaborations and recent patents.

The total market for drug-device combinations worldwide was valued at $5.4 billion in 2004 and is expected to rise at an average annual growth rate of 13.6% to $11.5 billion in 2010. The report contains:

• Analysis of the technologies for five areas of drug-device combination products, including antimicrobial catheters, biologic wound care products, bone graft substitutes and bone cements, drug-eluting stents and photodynamic therapy (PDT)
• Analysis of global markets for these products with forecasts to 2010
• Detailed discussion of the current regulatory environment for drug-device combination products and how this is affecting development and approval of such devices
• Further analysis of overall market trends and competitors and profiles of selected competitors in each category.

Worldwide revenue for contract manufacturing and research for the pharmaceutical industry was estimated at $100 billion in 2004 and is expected to rise at an average annual growth rate of 10.8% to $168 billion in 2009. The report contains:

• An overview of the contract business in the pharmaceutical industry
• Analysis of the quality assurance required, the regulatory environment and technology transfer aspects
• An overview of technological issues and trends
• Examination of the market's size by specific drug with forecasts through 2009
• Revenue analysis by bulk drugs and dosage forms like solids, liquids and semisolids, and separately for OTC and nutritional products
• Analysis of the contract research market, with forecasts through 2009
• Company profiles and market shares, where available.

The U.S. market for antiaging products and services in 2004 is expected to exceed $45.5 billion. Growing at an average annual growth rate of 9.5%, this market will reach nearly $72 billion by 2009. The report contains:

• A full discussion of factors impacting the U.S. market for antiaging products and services
• Analysis of products targeted at medical conditions associated with aging
• Analysis of antiaging appearance products and services
• Analysis of antiaging technologies and their impact on the market
• Market forecasts for all categories through 2009
• Overview of regulatory aspects.

The total U.S. market for advanced wound care was estimated at more than $1.7 billion in 2003 and is expected to rise at an average annual growth rate of 10.2% to $2.8 billion. The report contains:

• An overview of products and technologies included in this market
• An overview of markets in five general advanced segments: biological dressings, surgical sealants, synthetic dressings, other wound healing products and wound healing devices
• Product sales and forecasts for the U.S. market through 2008
• Competitive analyses for each segment
• Competitor market share estimates for each market segment for the 2003 base year.

The market for "new antibiotics" and HIV/AIDS treatments was $6.2 billion in 2003 and is rising at an average annual growth rate of 9.1%. It is expected to reach $10.1 billion in 2008. The report provides:

• A focus on products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
• Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
• Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
• Sales for 2003 of new antibiotics and HIV/AIDS drugs, with forecasts through 2008
• Trends based on projected sales through 2008 for new products, including supporting analyses for projections.

The total orthopaedic drug, implant and device market is expected to reach $44 billion by end of 2004. Rising at an average annual growth rate of 11%, the market is expected to reach $74.1 billion by 2009. The report contains:

• Analysis of the types of drugs, implants and devices used in orthopaedics
• Analysis of each technique with sales estimates and market projections through 2009
• A look at manufacturers, new products, and market share information
• Discussion of technological issues including the latest trends and developments
• Examination of government regulations listings of approvals of orthopaedic drugs, devices and implants from 2000-2004
• Discussion of patents in the industry and their significance.

For 2003, the total worldwide market for blood disorder treatments was estimated at $25.4 billion. Rising at an average annual growth rate of 6.7%, the market is expected to exceed $35 billion by 2008. The report contains:

• Identification of the different products used to treat various blood disorders
• Details on the blood disorder market size and its participants
• Discussion of products in research and development
• Details of the industry, its relationship to the health-care industry, its economic consequences and its participants
• Market forecasts through 2008 for the following product segments: anemia, hemophilia, neutropenia and thrombosis.

Emerging and updated drug marketing strategies are expected to contribute $181.2 billion of the $243 billion in U.S. drug sales in 2003 and grow to $313.3 billion of the expected 2008 total market of $362 billion. The report provides information on and analysis of:

• The ethical drug industry including description of the performance of major sectors of the total drug industry
• Patent expirations and patent extension activities
• The impact of formularies in deciding which drugs are prescribed
• Strategic market actions used by pharmaceutical companies to expand their market segments
• Expanded applications and life cycle management
• Prescription to OTC switches and branded generics and "off-label" use of drugs
• Mail-order marketing and pricing practices.

The world pharmaceutical industry stood at $592 billion in 2003, or 24% of the healthcare sector. Rising at an average annual growth rate of 8.8%, this market is expected to reach $938 billion in 2008. The report contains:

• Analysis of four sectors of the world pharmaceutical industry and major geographical markets: ethical, generic and OTC pharmaceuticals and biopharmaceuticals
• Analysis of the forces affecting the world pharmaceutical markets: buyers, suppliers, substitutes and new entrants
• Determination of their impact on market demand and growth
• Growth forecasts through 2008
• Detailed profiles of 25 leading pharmaceutical world markets
• R&D profiles, export-import profiles, pharmaceutical distribution and pricing, and reimbursement and regulation updates.

The total worldwide market for orphan drugs, including sales for nonorphan applications, is expected to rise at an average annual growth rate of 9.1% to reach $43.6 billion in 2008. The report contains:

• An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence, and advantages inherent in orphan drug designation
• Detailed discussion of successful orphan products, recently introduced products with an equivalent potential, and selected products in development
• Sales projections through 2008 for many of the 26 products analyzed
• A discussion of applications to specific orphan diseases for which products exist, and sales leaders
• An outline of legislation and regulation, including public and private agencies involved in support and development
• Analysis of the orphan drug industry, outlining leading companies and their successful
• Product strategies.

The total U.S. market for pharmacy automation was estimated to be $1.4 billion in 2003, and is expected to rise at an average annual growth rate of 11.7% to reach nearly $2.5 billion in 2008. The report provides:

• Pharmacy automation market analysis in the following areas:
        - inpatient and outpatient pharmacy automation
        - acute and long-term care and outpatient/fast-track clinical settings
        - pharmacy benefit management and other mail-order settings
        - retail pharmacy and hospital retail settings
• Detailed information on current and emerging products, and research and development
• Current market estimates and market forecasts through 2008, and competitive analyses.

The total U.S. market for substance abuse treatment and diagnostics reached $1.1 billion in 2003 and, rising at an average annual growth rate of 4.1%, will reach $1.3 billion in 2008. The following areas are addressed in:

• Stimulants, including tobacco, amphetamines, cocaine and crack
• Depressants, including sedatives and hypnotics, alcohol and opiates
• Hallucinogens
• Diagnostic testing, from point-of-care to home diagnostics
• Current and potential products and market drivers, with market forecasts to 2008
• Market participants and market shares.

The projected 2008 drug sales market of $490 million is highly segmented according to the price to the final buyer, whether cash customers, insurers/pharmacy benefit managers, health care providers, Medicaid, or other agencies of Federal or state government. This report provides:

• A market overview, covering overall size and price trends
• Analysis of private and public sector responses to rising prescription drug prices
• Analysis of the major price segments and the business and financial implications of these segments
• Market drivers and constraints
• Detailed U.S. market projections by price segment through 2008
• An examination of the long-term outlook for the U.S. prescription drug market.

By 2007, the U.S. and global market for psychotherapeutic drugs will reach $29 billion and $44.9 billion respectively. The report includes:

• Identification of mental disorders and incidence
• Current treatments
• Markets by product type and size, with forecasts through 2007
• Market drivers and future trends
• Market participants and their market shares
• Potential treatments in research and development.

The 2002 U.S. market for prescription ophthalmic drugs was $2.8 billion, and, rising at an average annual growth rate of 8.6%, will reach $4.5 billion in 2007. The study covers:

• Prescription ophthalmic drugs by disease
• Type and product type
• Major treatment areas namely, cataracts, glaucoma, ocular allergies, infections, inflammation, retinal treatments and other ocular treatments
• Products, current market estimates and market forecasts through 2007
• Supplemental data on global trends
• Industry structure.

The U.S. market for drug delivery systems in 2002 was $38.8 billion, and is expected to rise at an average annual growth rate of 11.3% and reach $74.5 billion by 2008. This report provides:

• An overview of the U.S. drug delivery market including the basic principles underlying different drug delivery systems
• Factors affecting drug delivery markets, including the regulatory environment
• A comprehensive analysis of the current market and its future direction with an emphasis on newer techniques and products
• Present and future trends in drug delivery technologies with market size and growth forecasts through 2008
• Growth by acquisition strategies and the collaborations by companies to get better delivery systems
• Profiles of market leaders.

The total U.S. market for bone and joint applications of regenerative medicine is projected to rise at an average annual growth rate of 8.5% to reach $1.4 billion in 2007. This report provides coverage of:

• Background demographics underlying the bone and joint market, regenerative technologies, and product development for other applications
• Applications, describing the leading diseases and disorders applicable to regenerative bone and joint technologies
• Products, with extensive descriptions and analyses of those used to treat bone and joint disorders and discussion of products in development
• Regulatory issues as well as recent bankruptcies among companies supplying regenerative products and the reasons for their financial difficulties
• Profiles of leading and emerging companies along with analyses of current and future positioning of their products and businesses.

The U.S. In Vitro toxicology market is expected to reach $1.96 billion by 2007 with pharmaceuticals accounting for more than 90% of the industry. Coverage of the report includes:

• Industry structure along with selected company profiles
• Relevant government agencies and other organizations affecting in vitro toxicology
• Available products and how these products are applied in the marketplace
• Market applications and relevant trends in these markets with five-year forecasts
• Technology overview that discusses current technologies and future trends.

By 2007, $26.5 billion will be spent on clinical trials and the number of trials will increase to 4506. This report focuses on:

• Influences on R&D of drugs and biologics
• Technologies
• Current and future trends in clinical trial research with five-year forecasts
• New technologies impacting the costs and processes of clinical trials
• Major product pipelines by physiological system and company
• Regulatory issues.

Drugs for the elderly are expected to reach nearly $80 billion by 2007. This report provides coverage of:

• 10 segments in which prescription drugs are used
• Current drugs for these areas, and research and development
• Market size
• Competitive structure and market shares
• Market projections through 2007
• Company profiles

More than a dozen new prescription products are in clinical development and will contribute to the growth in the $8.7 billion 2008-projected market. This report includes:

• Summary of significant fungal diseases, drug resistance and emerging antifungal agents
• Discussion of leading antifungal agents and agents in development, and their potential impact
• Breakdown of the worldwide market for antifungal drugs, and market shares of leading companies
• Companies and their innovative products in development
• Market trends based on projected sales for new products
• Sales for the year 2001 by antifungal drug class, and forecasts from 2002 through 2007.

In 2001, the global market for pharmaceutical (drug) inert ingredients was an estimated 7.25 billion pounds, of which water, accounted for about 77% of the total. This study covers in depth many of the most important technological, economic, environmental, political and other considerations relating to pharmaceutical inert ingredients, and is global in its analysis. It includes:

• An overview of the industry
• A discussion of formulated drug sales and their inert ingredients, prescription (Rx) and over-the-counter (OTC) markets, labeling, and trends, issues and regulations
• Product and market analysis of inert ingredients covering materials, functionality, dosage form, and Rx vs. OTC markets
• Industry structure, regulatory and international aspects of the inert ingredients markets and businesses
• Profiles of inert ingredients supplier companies.

The U.S. drug industry is an evolving industry driven by scientific and technological advances, new drug discoveries, advances in therapeutic knowledge and changes in government and regulatory controls. Innovative new technologies have led pharmaceutical researchers to many new discoveries, many of which are derived from new knowledge of the cellular mechanism of disease. Increased knowledge of DNA and cellular biology has opened new avenues of drug development. This industry has been quite successful since BCC last examined it in July 1999. Much of this success is demonstrated by the discovery of new drugs that generate billion-dollar annual sales. These "block buster" drugs, while providing wonderful benefits to patients, have also caused financial concerns both to patients and to insurance companies. The U.S. drug industry has been under attack for the high cost of these drugs, particularly among the Medicare population, and politicians have promised some legislative relief. In this report BCC provides information on the related advances in technology, the performance of major sectors of the drug industry, product trends, changing corporate objectives and strategies, the result of joint ventures, licensing, marketing alliances, mergers and acquisitions, the introduction of new drugs, pricing strategies, the influence of HMOs and an aging population, and the worldwide aspects of the market. From the analysis of this data BCC provides market forecasts for through 2007 for the current and future trends in market size, market participants, product lines, and consumer attitudes. Included in this study are all products classified as drugs, both Rx and OTC.

Following several years of single-digit average annual growth, from 1996 to 1999. However, the U.S. generic drug industry experienced double-digit growth during 2000 and 2001 and is projected to continue such growth throughout the forecast period (to 2006). This report takes the pulse of the current generic drug market and industry at a time when big changes are afoot. From 2001 to 2006, some $37 billion worth of branded drugs will lose patent protection. In 2000, generics held about 42% of the prescription drug market by volume and this share is expected to increase to nearly 50% by 2006. This report provides forecasts of revenues by therapeutic category for the U.S. prescription generic drug market and includes assessment and forecasts of selected international markets for generic drugs. Also included in the report are discussions of legislative changes (in particular, changes to Medicare), patent expirations on blockbuster drugs and other factors that will affect the generic drug market. Strategies employed by generic drug firms to succeed in this highly competitive and relatively low profit margin industry are provided, as well as strategies employed by branded product companies to protect patents and extend the market life of their products. Profiles are  provided for leading generic drug companies and generic drug subsidiaries of branded product companies.

This in-depth study analyses markets for drug use and abuse testing services. The current $1.6 billion-per-year market, which represents more than 50 million drug tests, will be changing due to testing policies and technologies. This study looks at the current status of drug testing policies, practices, and technology being used in many sectors of society, such as government agencies, public and private corporations, and public and private school districts. Drug testing technology development is also discussed. Market forecasts are given for the period 2002 through 2007.

This new BCC report explores the dynamic and changing environment of prescription allergy treatments and analyzes the major issues affecting the market. This market has been under intense scrutiny from all different factions and the major decisions and changes that are occurring will likely shape the market of the future. The report covers antihistamines and combinations, decongestants and combinations, corticosteroids and mast cell stabilizers. The purpose of the report is to assess the market presence, production base, corporate ethos, and recent and future strategic marketing activities of manufacturers involved in this market. The report discusses issues from the pharmaceutical manufacturer standpoint, the insurance industry standpoint and the public standpoint. Recommendations of solutions, medico-legal repercussions, and progress in allergy treatment development are also discussed. Key participants in the market are profiled using up-to-the-minute data and analysis from the very latest manufacturer and supplier interviews. The market analysis offers manufacturer and share information for all major products. Patient populations and market estimates as well as growth rates are presented for 1999, 2000, 2001 and 2006.

The U.S drug and cosmetics industries have seen significant growth from the aging baby boomer population, which has changed considerably since BCC undertook its last study in 1997. Many of these changes are medically driven while others are due to image concerns. In either case, these situations are causing this group to purchase cosmetics and preventative agents. Not only does the report focus on the demographics and the behavior patterns of the baby boomer generation, it also examines the group's significance as a major market segment within the U.S. drug and cosmetics industries. From this analysis BCC provides estimates for the current and future trends in market size, market participants, product lines, and consumer attitudes. It offers aggregated estimates on the major markets driven by the aging baby boomers, where forecasts run from 2001 through 2006. Included in this study are all products classified as drugs, both Rx and OTC; cosmetics; and other products such as vitamins and herbal remedies. This study will prove particularly beneficial to pharmaceutical and cosmetics industry producers, suppliers, investors, venture capitalists, and other participants as well as those interested in demographic trends within these industries.

The continuing emergence of antibiotic resistance threatens to reverse the progress made during the latter half of the 20^th century to effectively treat bacterial and other infectious diseases. Solutions to this dilemma involve management approaches on a worldwide scale, such as the implementation of rigorous surveillance of resistant organisms, better education of healthcare workers about appropriate use of antibiotics and closer monitoring of antibiotics used in animals and plant crops. Dovetailing with these organizational activities is the need for new and effective antibiotic drugs. This report provides an in-depth look at antibiotic resistance, its causes, the extent of its impact and strategies to combat it. The report focuses primarily on recently introduced and in-development antibiotic products that specifically address the problem of bacterial resistance. The mechanisms by which these drugs function to outwit resistant microbes, are described as is the likelihood that resistance will develop and in what timeframe. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effect on the market are assessed. Forecasts for the various markets discussed will be provided through 2006.

Wound dressings and other types of wound healing technologies are experiencing fast-paced development and rapid growth. As the patient population ages, and as regulatory and cost issues reduce hospital stays and increase home care and other forms of long-term care, awareness is growing of the real costs associated with the management of wounds. Advanced dressings are accelerating healing rates, lowering infection rates and improving patient comfort. This report covers the many developments related to wound care technologies in detail. This document analyzes the present status and forecasts for the market.

New developments in vaccine technology that have emerged over the past decade have transformed this relatively lackluster, price-competitive market sector into a technology-driven industry characterized by increasing annual growth rates that approached 10% during the late 1990s. Prophylactic vaccines for children and adults have been the mainstay of this market and although dramatic innovations in these preventive products are not anticipated, this category will enjoy continued modest growth. A tidal wave of growth in the vaccines market is expected with the introduction of therapeutic vaccines currently in development to treat acquired-immune deficiency syndrome (AIDS), cancer and other major diseases. DNA-and protein-based therapeutic vaccines that boost the immune response to cancerous cells will add a powerful new component to standard treatments for cancer. The first cancer vaccine is projected to enter the market in 2002. Recent product introduction and products projected for introduction during the forecast period (2001 to 2006) are discussed in this report, with sales projections provided. Traditional vaccines as well as those incorporating antibodies, growth factors, cytokines, hormones and recombinant proteins and peptides are assessed. Regulatory trends, such as significant changes in vaccination programs recommended in 1999 by the Centers for Disease Control and Prevention (CDC), are discussed and their affect on the market is analyzed. In addition to analyses of leading competitors in the current worldwide vaccines market, this report assesses companies poised to introduce products during the forecast period and how this will change the face of the competitive environment.

This updated and informative BCC report assesses the impact of new entrants into the Rx to OTC switched market. The report addresses issues that are influencing the switches from Rx to OTC status, and other factors that are influencing the market. The report focuses on the various pharmaceutical segments where historically there have been switches, pending switches, and potential switches that Augustoccur during the forecast period. Market size for OTC switched products that are currently available is provided. A detailed discussion of products that are being considered for switching is given, and the criteria for switching are addressed. Markets are divided according to product category, including analgesics and nonsteroid anti-inflammatory drugs; antifungals and anti-infectives; cough, cold, allergy and asthma; gastrointestinal products; and other small products categories such as smoking cessation, alopecia, etc. Patient populations and market estimates as well as growth rates are presented for 1998, 1999, 2000 and 2005. Competitor market shares and profiles are provided for leading companies currently active in the market.

This study explores the issues driving the development and commercialization of pharmaceutical bulk actives. Pharmaceutical actives are the substances in drugs that perform the desired therapeutic actions. The scope of this study is worldwide. This study is not an audit data report of the kind offered by pharmaceutical tracking services. Rather, it offers aggregated estimates of specific pharmaceuticals or pharmaceutical groups by all providers combined. The objectives of this study are to examine the pharmaceutical actives (bulk pharmaceuticals) market, and to: quantify the bulk production of pharmaceutical actives in both kilograms and dollars, identify producers as opposed to formulators of finished dosage forms, describe and detail the manufacturing processes for the production of pharmaceutical actives, and examine the directions and dynamics of new developments in this marketplace.

Cardiovascular drugs have been the leading class of drugs by worldwide sales for nearly three decades. In 1999, the market for cardiovascular pharmaceuticals was estimated at $46 billion worldwide, and the leading 10 products in the class generated sales of nearly $12 billion. This report discusses the primary categories of currently available cardiovascular agents, including adrenergic inhibitors; adrenergic stimulators; angiotensin converting enzyme (ACE) inhibitors; angiotensin II receptor blockers; anticoagulant, antiplatelet and antithrombolytic inhibitors; beta blockers; calcium channel blockers; diuretics and enzymes; steroids and steroidal glycosides; vasodilators; vasopressors; and selected other agents, including monoclonal antibodies. Market forecasts and trends are provided for these agents. In addition, market forecasts and trends by disease indication are provided for drugs that treat angina, arrhythmia, cardiac arrest, cardiomyopathy, edema, heart failure, hypercholesterolemia, hypertension, hypotension and myocardial infarction. Topics covered in this report include the current and future impact of managed care on the use of branded and generic cardiovascular agents, as well as revolutionary technologies in development--such as emerging treatments for stroke and gene therapy--that may transform this market. The competitive environment is examined, with a special focus on how new products and technologies as well as acquisitions and mergers are likely to reshuffle the leading manufacturers in the cardiovascular arena.

This new and informative BCC report assesses the impact of new technology and products on the market for therapeutics and diagnostics for sexually transmitted diseases and disorders. The report addresses issues that are shaping the sexually transmitted disease market, and demographics that are influencing the market. The report focuses on the various pharmaceutical therapeutic/diagnostic preparations. Market size for products that are currently available is provided. A detailed discussion of products in research and development for sexually transmitted diseases, including HIV/AIDS, is also provided. Markets are divided according to type of disorder, including Bacterial Vaginosis, Chancroid, Chlamydia, Genital Herpes, Genital Warts, Gonorrhea, Hepatitis B, HIV/AIDS, Pediculosis Pubis, Syphilis, and Trichomoniasis. Patient populations and market estimates as well as growth rates are presented for 1998, 1999 and 2005. Competitor market shares and profiles are provided for leading companies currently active in the market.

The U.S. pharmaceutical industry offers increasing opportunities for advanced drug delivery systems to encroach upon and give a competitive edge over their conventional counterparts. This updated BCC report provides a comprehensive analysis of these systems, including novel technologies with non-term market impact and emerging ones with potential usage in the future. The report also makes market forecasts and discusses trends for controlled release, site-selective and transmucosal systems.

The market for psychotherapeutic drugs represents the third largest therapeutic category in terms of worldwide sales and approached $20 billion in 1999. This sector is characterized by fewer but bigger-selling products than are the leading therapeutic categories, cardiovascular treatments and anti-infective agents. This report includes the following categories of psychotherapeutic products: Alzheimer's disease therapies, antidepressants (which include treatments for addiction), anxiolytics (which include treatments for panic disorder, obsessive-compulsive disorder and related diseases), attention deficit hyperactivity disorder treatments, narcolepsy treatments, treatments for obesity, antipsychotic agents and sedatives/hypnotic. Sales for each sector are provided for 1998, 1999, and forecast to 2005.

In this study, the European pharmaceutical industry is analyzed and market trends and forecasts are predicted into the year 2003. A major focus of the report is the regulatory environment of the European Union and the impact of pressure to keep drug prices down in order to support the public health care systems of Member States while remaining globally competitive. Industry, national and European Union strategies are presented with expert analysis. Profiles by country as well as industry leaders in patented, generic and OTC drug categories are examined. Major therapeutic categories are included as well as the emerging European biotech industry. Highlights of the report also include the shift to a Single Market with the gradual harmonization of prices, parallel trade, and the current and future impact of the EURO. Leading industry and government officials were interviewed during the preparation of this report.